EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Olema Oncology","sponsor":"Paradigm BioCapital","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Announces Combined Financing for up to $180 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Olema Oncology Announces Expansion of Collaboration Agreement with Novartis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for Palazestrant

    Menu

    Palazestrant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Olema Oncology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

              Details:

              Under the collaboration, Novartis will increase the size of the ongoing Phase 1/2 study testing OP-1250 (palazestrant), an orally-available small molecule with dual activity as both a complete ER antagonist and a selective ER degrader, in combination with ribociclib.

              Lead Product(s): Palazestrant,Ribociclib

              Therapeutic Area: Oncology Product Name: OP-1250

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration October 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Olema Oncology

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Olema Oncology Announces Combined Financing for up to $180 Million

              Details:

              Olema intends to use the net proceeds to fund research and development of palazestrant OP-1250 (palazestrant), a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist and a selective ER degrader.

              Lead Product(s): Palazestrant,Palbociclib

              Therapeutic Area: Oncology Product Name: OP-1250

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Paradigm BioCapital

              Deal Size: $130.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement September 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY